Bellevue Asset Management (Switzerland)’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-14,900	Closed	-$1.45M	–	154
2015 Q1	$1.45M	Buy	+14,900	New	+$1.58M	0.2%	105

Bellevue Asset Management (Switzerland)'s GEVA Position: Q2 2015 in Review

Bellevue Asset Management (Switzerland) sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 14,900 shares — an estimated $1.45M sold.

Bellevue Asset Management (Switzerland) first reported a position in GEVA in Q1 2015 and held it in 1 quarter. The position peaked at $1.45M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Bellevue Asset Management (Switzerland) reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Bellevue Asset Management (Switzerland) sold 14,900 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.45M.
Bellevue Asset Management (Switzerland) first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015 and held it in 1 quarter.
Bellevue Asset Management (Switzerland)'s SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.45M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q2 2015, filed 12 Aug 2015.